Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03849612 · ClinicalTrials.gov registry record · NA
A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus
A NA study of Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03849612: Completed NA study of Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company.
NCT03849612 is a NA study of Type 1 Diabetes Mellitus that has completed, run by Eli Lilly and Company. The registered enrollment target is 10 participants, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03849612, a NA study of Type 1 Diabetes Mellitus, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased.
Primary Outcome
Number of AEs
Conditions Studied
Interventions
- DEVICE AID System
- DRUG Insulin Lispro
Study Locations (1)
California
- Diablo Clinical Research - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2019-03-27 |
| Phase | NA |
What the finished NCT03849612 record still lists
NCT03849612 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 172-participant average among 112 other Type 1 Diabetes Mellitus trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which AID System is the first listed.
NCT03849612 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03849612 about?
NCT03849612 is a clinical study titled "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus". The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased.
What is the current status of trial NCT03849612?
This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2019-02-21. Estimated completion is 2019-03-27.
What conditions does trial NCT03849612 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT03849612?
The interventions under investigation include: AID System (DEVICE), Insulin Lispro (DRUG).
Who is sponsoring clinical trial NCT03849612?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03849612 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03849612's enrollment target sits among peer trials
10 106th of 112 higher than 4 of 112 other Type 1 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM
RECRUITING · NA
-
Implementing the Spotlight AQ Platform in Adolescent/ Young Adult (16-25 Years Old) Type 1 Diabetics (T1D)
RECRUITING · NA
-
A Hybrid Effectiveness-implementation Trial to Reduce Diabetes Distress in Teenagers
RECRUITING · NA
-
PACTAID App in Adults With Type 1 Diabetes to Help Manage Exercise
RECRUITING · NA
-
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
RECRUITING · NA
-
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI